Displaying 11 results for

States Support Postpartum Health with Medicaid Expansions astho, association of state and territorial health officials, 2023 state legislative session, medicaid expansions, postpartum health, the consolidated appropriations act, national women s health week, postpartum coverage, affordable care act, premium tax credits, affordable care, 12 weeks, united states, extended postpartum coverage, health a priority, medicaid program, national women s health, mother s day, 2023 legislative, vaginal birth, physical activity, women s health week, postpartum care, coverage for 12 months, 60 days, state plan amendment, care act, postpartum depression, health care Sowmya Kuruganti National Women’s Health Week reminds us that postpartum care is critical for the long-term health of the birthing parent and baby. National Women’s Health Week’s 2023 theme—Women’s Health, Whole Health: Prevention, Care and Wellbeing—is a reminder that postpartum care is critical for the long-term health of the birthing parent and baby. The first year after pregnancy can be full of physical, emotional, and mental health challenges that have long-term or even life-threatening health impacts without timely diagnosis and treatment. In September 2022 CDC reported that 23% of pregnancy-related deaths occur from seven to 42 days postpartum, and 30% of deaths occur 43-365 days postpartum. Among all pregnancy-related deaths occurring from 2017 to 2019, approximately 84% were deemed preventable. Black and American Indian and Alaskan Native <!--(AI/AN)--> women have two to three times higher rates of pregnancy-related death compared to white women. These disparities, like others, are driven by social and economic factors that are rooted in structural and systemic racism and discrimination. Health insurance coverage is one such factor that supports positive maternal health outcomes by facilitating access to care before, during, and after pregnancy. In the United States, 40% of births are covered by Medicaid, which is the primary source of health coverage and access to care for those of low income. Organizations like ASTHO and the Association of Maternal and Child Health Programs support extending Medicaid coverage through one-year postpartum to combat disparities in maternal health outcomes. Federal Legislation for Postpartum Coverage under Medicaid For the majority of states that have adopted Medicaid expansion under the Affordable Care Act (ACA), all people with income up to 138% of the federal poverty level (FPL) are eligible for Medicaid. In states without Medicaid expansion, pregnant people can be eligible for coverage during pregnancy and up to 60 days postpartum under federal law. After 60 days postpartum, these people may lose coverage for the rest of the year-long postpartum period based on general state Medicaid eligibility requirements. Prior to 2021, states could extend Medicaid coverage to postpartum people through a section 1115 demonstration waiver or through state funds. The enactment of the 2021 American Rescue Plan Act, gave states another option to extend Medicaid coverage to 12 months postpartum via state plan amendment for five years. So far in 2023, CMS has approved the State Plan Amendments for five states (Alabama, Arizona, Colorado, Oklahoma, and Rhode Island) implementing a 12-month postpartum expansion. To date, a total of 33 states have expanded Medicaid coverage to 12 months postpartum via Section 1115 demonstration waiver or state plan amendment. 2023 State Legislative Session Depending on states rules for modifying Medicaid coverage the legislature may need to direct the health department to submit a state plan amendment. So far in 2023, three states enacted legislation related to expanding coverage to 12 months postpartum. In Mississippi, SB 2212 authorizes the state’s Division of Medicaid to provide 12 months continuous postpartum coverage to people who qualify. Utah’s SB 133 extends coverage for 12 months postpartum for women eligible for Medicaid during pregnancy. In Wyoming, HB 4 temporarily extends Medicaid coverage for qualifying pregnant women for 12 months postpartum, ending March 31, 2027. Other states introduced bills to extend postpartum coverage during this session. The Alaska Legislature passed legislation (SB 58) directing the Department of Health to submit a state plan amendment extending postpartum coverage to 12 months, and to raise the household income level for eligibility to 225% of the FPL. The bill is currently awaiting action by the governor. Iowa introduced legislation (SF 57) to enact postpartum coverage for 12 months postpartum by Medicaid State Plan Amendment. This would extend the current 60-day postpartum coverage for Medicaid beneficiaries. The Missouri legislature passed (SB 45) that would extend MO HealthNet postpartum coverage from 60 days to 12 months postpartum for women who are either currently receiving or eligible to receive aid to families with dependent children, or eligible to receive benefits via the income eligibility standard. Pregnant women eligible for MO HealthNet and receiving mental health treatment for postpartum depression, related mental health conditions, or substance abuse treatment within sixty days of giving birth would remain eligible for benefits for those services for an additional 12 months. The bill is currently awaiting action by the governor. Nebraska introduced legislation (LB 419) to extend postpartum coverage for 12 months postpartum that would extend the current 60 day postpartum coverage. Texas introduced legislation (HB 12) to extend postpartum coverage to 12 months; it has passed in the House and is now pending in the Senate. Its passage would significantly change the current coverage structure, which uses state funds to provide postpartum people a limited package of postpartum services through the Healthy Texas Women program under HB 133, and subsequently submitted 1115 waivers to draw down federal funds for the program and extend coverage to six months postpartum. Wisconsin introduced companion bills (AB 114/SB 110) extending postpartum coverage for 12 months postpartum for women eligible for Medicaid during pregnancy. This action would extend coverage from the current 60 days and amend the previous 90-day Section 1115 Waiver submitted in 2021. Studies have demonstrated numerous benefits of extending Medicaid coverage for postpartum people and, given these positive impacts, ASTHO expects that more states will take action to extend Medicaid to 12 months postpartum. ASTHO will continue to monitor and report on this essential maternal public health issue. website yes

The 2020 holiday season is coinciding with a nationwide surge of COVID-19 cases. With great concern that holiday travel to see loved ones may exacerbate community spread of the virus, many states are increasing public health measures before the winter holiday season. As of November 16, 2020, 13 states and D.C. had a quarantine requirement for out-of-state travelers. The U.S. territories also have instituted travel restrictions to limit the spread of COVID-19.

This brief focuses on how telehealth expansion during the COVID-19 pandemic has increased access to care for pregnant and postpartum women, and made maternal and child health care services like doulas and midwives more accessible.

Opportunities for Public Health Agencies to Advance Sustainable Financing of Community Health Worker Programs Advancing Sustainable Financing of Community Health Workers Explore how health officials can play key roles as funders, administrators, and policy designers to advance sustainable financing of community health workers. Many states face upcoming funding gaps for community health worker (CHW) positions, with COVID-19 related grant funding streams expiring. Concurrently, many states are rapidly beginning to cover CHW services under Medicaid. In addition, Medicare launched a new reimbursement opportunity for CHWs in January 2024. These factors create an opportunity for state and territorial health agencies to develop or contribute to equitable reimbursement and robust implementation. This report details how health officials can play key roles as funders, administrators, and policy design champions to ultimately advance sustainable financing of CHW services. Get the Report (PDF) website yes

Federal and state legislation can play a role in promoting positive infant mental health by providing funding and policies that support early intervention, caregiver assistance, and the creation of nurturing environments conducive to their emotional well-being.

When the COVID-19 pandemic began the need for greater access to virtual reproductive health care services increased dramatically. Telehealth increased access to providers, eased workflows and infection protection for clinical staff, and reduced interruptions in care for many patients.

This report is on the overlap of climate change and environmental justice.

ASTHO staff identified a range of evidence-supported policies considered by state legislatures that could prevent ACEs. This report synthesizes these research and policy proposals and is intended for public health practitioners and policymakers who are considering adopting similar policies.

How the Emergence of Xylazine Impacts Overdose Prevention Policy overdose prevention policy, overdose crisis, fatal overdoses, emergence of xylazine, illicit drug supply, toxicological testing, withdrawal symptoms, xylazine test strips, drug paraphernalia laws, drug checking, legislative action, drug supply, substance use disorders, controlled substance, opioid use disorder, centers for disease control, health care, harm reduction services, psychoactive substances, department of public health, illegal drug, type of drug, opioid crisis, prescription opioid, astho, association of state and territorial health officials JoAnne McClure, Victoria Pless How states are considering overdose policy changes as xylazine continues to emerge in the illicit drug market. Developing and adopting policies to reduce fatal overdoses can help public health leaders address the ever evolving and complex national overdose crisis. More than 109,000 fatal overdoses occurred in 2022, with the majority involving illicitly manufactured fentanyl. Adding to the overdose challenge is the emergence of xylazine, a non-opioid tranquilizer (i.e., sedative), that is being increasingly mixed with fentanyl in the illicit drug supply. As of November 2022, xylazine was found in the illicit drug supply in 48 of 50 states and Puerto Rico. Xylazine is currently associated with one in ten fatal fentanyl (11%) overdoses, a near-threefold increase from 2.9% in 2019. Toxicological testing for xylazine is not uniform and, as a result, its involvement in fatal overdoses may be underestimated. Some states have taken initiatives such as Indiana (HB 1286) and South Carolina, to improve the consistency of toxicological testing for xylazine. With xylazine’s addition to the overdose crisis, states are beginning to adopt laws to better regulate the supply of xylazine and detect its presence in the illicit drug supply. What is Xylazine? Xylazine, also known as “tranq” or “tranq dope,” is a central nervous system depressant causing drowsiness, slowed breathing, reduced heart rate, and hypotension, which can increase the risk of a fatal overdose. Xylazine is approved for veterinary use in the United States but is not FDA-approved for human medicine. Xylazine, can be added to substances that are ingested orally, snorted, sniffed, or—mostly commonly—injected intravenously, and has been added to or used to cut heroin and fentanyl to prolong their effects. People who use drugs may be unaware of xylazine’s presence, which can put them at a higher risk of fatal overdose. Xylazine use is associated with skin ulcers, lesions, abscesses that left untreated, can lead to amputation. People who develop a physical dependency on xylazine may develop severe withdrawal symptoms. Although symptoms of xylazine use and opioid use are similar—making it difficult to differentiate whether someone has used one or both substances—overdose reversal agents (e.g., naloxone) do not counteract the effects of xylazine. Public health leaders still recommend that naloxone be administered for a suspected opioid overdose because xylazine has been detected in substances alongside fentanyl. For a person experiencing a xylazine-involved overdose, public health leaders emphasize the need to seek treatment beyond naloxone. In addition to public health’s work to address xylazine in the illicit drug supply, some state and territorial legislatures are expanding or protecting access to xylazine test strips as well as steps to limit access to xylazine through the state drug schedule. Legalizing Drug-Checking Equipment Drug-checking equipment, such as fentanyl test strips, are evidence-based interventions that allow a person who uses drugs to test their supply for an adulterated substance. State drug paraphernalia laws historically prohibited drug checking equipment, limiting the possession, distribution and use of items like fentanyl test strips. To make fentanyl test strips more widely available to prevent overdose, legislatures rapidly changed their laws to either explicitly legalize fentanyl test strips or generally legalize drug checking equipment. As of July 5, 2023 more than 33 jurisdictions legally authorize the use of fentanyl test strips, 12 of which (Alaska, Colorado, Guam, Maine, Maryland, Nebraska, New York, the Commonwealth of the Northern Mariana Islands, Pennsylvania, South Carolina, Utah, and Vermont) generally authorize the possession and use of drug-checking equipment. Similar to fentanyl, people may not know whether they are exposed to xylazine when using other substances, increasing the risk for harm. New test strips can detect the presence of xylazine, however state drug paraphernalia laws that criminalize drug checking equipment may limit the accessibility of xylazine test strips to prevent overdose. In 2023, at least three states—Illinois (HB 3203), New Hampshire (HB 287), and Utah (SB 86)—enacted legislation to authorize or decriminalize use of drug-checking equipment for fentanyl and xylazine, ensuring that xylazine test strips are lawful and able to be distributed. Additionally, states that previously passed legislation to allow for fentanyl-specific drug checking are amending their statutes to include all drug checking to ensure the legal possession of xylazine test strips. For example, Delaware enacted (SB 189) that specifically legalized xylazine test strips. Two other states—Vermont (H 222) and New Jersey (SB 3957)—enacted laws expanding the authorization of fentanyl test strips to allow for all harm reduction supplies, including drug checking equipment, which would permit the use of xylazine test strips. The Question of Scheduling Drugs are scheduled based on their acceptable medical use and potential for misuse and severe psychological and/or physical dependence, with drugs in Schedule I being the most tightly regulated. Xylazine is not a controlled substance under the federal Controlled Substance Act so it is not DEA scheduled or controlled. Nevertheless, xylazine is subject to FDA regulation under the federal Food, Drug, and Cosmetic Act and state law. Prior to 2023, only two states directly or indirectly scheduled xylazine. Florida codified xylazine as a Schedule I substance in 2016, and xylazine could fall under Massachusetts’ Schedule VI designation, which applies to prescription drugs. As state and territorial leaders take steps to schedule xylazine, policymakers should consider whether scheduling or other criminal penalties will deter people from seeking care if they fear being arrested for unknowingly testing positive for exposure or xylazine use. Another consideration for leaders before scheduling xylazine is whether scheduling will also make possession of test strips illegal under the jurisdiction's drug paraphernalia law. In 2023 at least nine states–Delaware (SB 189), Illinois (HB 3873), Louisiana (HB 106), Michigan (HB 4913), New Jersey (A 5448), New York (A 5914), Oklahoma (SB 668), Rhode Island (HB 5922), and West Virginia (SB 546)—considered legislation to schedule xylazine as a controlled substance. Of those, Delaware, Rhode Island, and West Virginia enacted laws scheduling xylazine in 2023. In addition to legislative action, at least two governors (Ohio and Pennsylvania) took executive action to schedule xylazine. ASTHO’s overdose prevention and state health policy teams continue to monitor these important public health issues. website yes

Over the past several years, states and jurisdictions have continued to implement important policies to reduce tobacco and nicotine use, including increasing tobacco prices, expanding areas deemed “smoke-free,” limiting the sale of flavored tobacco products, and supporting tobacco cessation programs.

ASTHO Celebrates Women’s History Through the Decades ASTHO, association of state and territorial health officials, public health infrastructure, vice president, population health, health science, health system, public health workers, american women, career path, environmental health, public health mph, national women s history, international women s day, public health careers, health education specialist, week of march, history month, master of public health, black women, women s history week, women s history, public health work, public health leadership, woman president, public health practitioner, racism and sexism, public health system, women s history month, women leaders, women in public health Kimberlee Wyche Etheridge ASTHO | Celebrating ASTHO's past, present, and future of women in leadership. With a movie ticket costing $2.50 and gas hovering at $1.10 / gallon, the year 1984 ushered in many new eras. Apple debuted the Macintosh personal computer with its Superbowl commercial based on George Orwell’s dystopic novel in the Winter. Over the next generation, this technology would change the way we interact with the world. Prince’s Purple Rain and the accompanying concert-type movie were released, ushering in a new generation of forever fans. Space travel catapulted into the future with the launch of the space shuttle Discovery, which flew an additional 38 times. Childhood hunger took center stage with the release of the benefit song, “Do They Know It’s Christmas?” by Band Aid, which would sell millions of copies and raise millions of dollars. It was the Eighties—a key decade in U.S. history. It also marked a critical first in ASTHO’s history. ASTHO has a long history of pioneering women leaders. Below, you'll find several of them whose work has inspired mine. (Read the full list of ASTHO's women presidents.) 1980s After 42 years of public health work and leadership, ASTHO elected its first woman president—Kristine Moore Gebbie, DrPH, RN (alumni-WA)—in 1984. Gebbie was an educator who taught generations of nursing students around the world. She was a public health practitioner and served as Secretary of Washington State’s Department of Health. Her legacy highlights the importance of working across multiple levels of government and healthcare agencies, especially as it relates to preparedness. As ASTHO president, she was a trailblazer, best known for her commitment to work focused on AIDS. While in this role, she was tapped to serve as the first White House AIDS Policy Coordinator. She received numerous awards and accolades from many different organizations, including the American Nursing Diagnosis Association (NANDA). 1990s In 1992, Joycelyn Elders, MD (alumni-AR) also celebrated a first—becoming ASTHO’s first African American woman president. Elders served as the Director of the Arkansas Department of Health. Her public health accomplishments include reducing teen pregnancy in her state, increasing early childhood screenings as well as the percent of children immunized at 24 months. During her time in Arkansas, she was recruited to serve as Surgeon General, where she became the first African American—and only the second woman—to hold the post. She contended with both racism and sexism while in the job, and despite criticism and waning support from the administration, she stayed true to her public health beliefs. She fervently believed that poverty plays a critical role in public health crises such as teen pregnancy, and that education is as an essential strategy to breaking the cycle of poverty. She became the first person to be board certified in pediatric endocrinology. She has published more than 100 papers focused primarily on juvenile diabetes and adolescent health. 2000s Known for saving many lives by successfully cutting smoking rates by one-third during her time as Washington State Secretary of Health, Mary Selecky (alumni-WA) served as ASTHO president in 2003 and 2004. She holds the title as one of the nation’s longest serving secretaries of health having worked under three governors. During her time as the top state health official, Selecky moved Washington to become one of the first state health agencies to receive national accreditation. Childhood immunization rates in the state catapulted from among the bottom in the nation to in the top third. She worked to improve the state’s public health system after a 2001 earthquake. As ASTHO president, Selecky worked to elevate ASTHO’s status as a vital partner after the 9/11 terrorist attacks. She worked to ensure that public health preparedness funds were granted to health departments. 2010s Jewel Mullen, MD, MPH (alumni-CT) was serving as the Commissioner for the Connecticut Department of Public Health when she was elected President of ASTHO in 2014. During her time in Connecticut, Mullen focused on the state’s public health system, specifically chronic disease prevention programs and improving coordination between public health and medical care. She was also a crucial figure in bringing the community to the public health table. She created an Office of Health Equity Research, Evaluation and Policy while in her role to ensure integration of health equity in the states programming. Mullen used her ASTHO presidential challenge to highlight healthy aging and issue a call to action to help older adults live and age well in their communities. Through her Presidential Challenge, states committed to healthy and safe community environments, injury and falls prevention, empowered people, Alzheimer’s plan, active living, and clinical and community preventive services. Nicole Alexander-Scott, MD, MPH (alumni-RI) was elected ASTHO president in 2018. In that role, she led a presidential initiative encouraging state, local, tribal, and territorial health departments to build healthier, more resilient communities through community-led, place-based approaches. This initiative mobilized strategic investments to address socioeconomic and environmental determinants of health to transform systems and policies in ways to empower local communities. Alexander-Scott has also worked as a specialist in infectious diseases for children and adults. She is board certified in pediatrics, internal medicine, pediatric infectious diseases, and adult infectious diseases, and served as faculty at Brown University in pediatrics, medicine, and public health (with a focus on health services, policy, and practice). She continues to work with ASTHO to promote health equity. 2020s Rachel Levine, MD (alumni-PA) served as president of ASTHO in 2020. She is the first openly transgender woman to serve in the role. Levine is a pediatric and adolescent medicine physician and an educator. In 2015, while practicing clinical medicine at the Penn State Hershey Medical Center, she was nominated by the governor-elect to serve as Pennsylvania’s physician in general. Two years later, she was named as Pennsylvania Secretary of Health. Levine led the state through the COVID-19 public health response and helped the state respond to the growing opioid epidemic. While serving as ASTHO president, the White House nominated Levine to serve as Assistant Secretary for Health. She achieved another first when she was commissioned as the first woman four-star admiral in the U.S. Public Health Service Commissioned Corps. She remains a strong advocate for the well-being of LGBTQI+ youth. Continuing in this strong tradition of trailblazing women in leadership, Anne Zink, MD (SHO-AK) took the reins as ASTHO President in September 2022. Zink plans to focus her presidency on improving health information systems to empower the public, healthcare providers, and the public health workforce with the tools and information they need to promote individual and population health. There are others who have helped pave the way for future women leaders at ASTHO. This month of March, we celebrate all the past, present, and future women who have served as Presidents of ASTHO. We are because they were. ASTHO's Women Presidents: 2023  Anne Zink, MD, FACEP (SHO-AK) 2021  Rachel Levine, MD (alumni-PA) 2019  Nicole Alexander-Scott, MD, MPH (alumni-RI) 2015  Jewel Mullen, MD, MPH, (alumni-CT) 2009  Judith Monroe, MD (alumni-IN) 2007  Mary M. Hansen, RN, PhD (alumni-IA) 2006  Leah Devlin, DDS, MPH (alumni-NC) 2004  Mary C. Selecky (alumni-WA) 2003  Mary C. Selecky (alumni-WA) 2000  Patricia A. Nolan, MD, MPH (alumni-RI) 1993  Molly Coye, MD (alumni-CA) 1992  M. Joycelyn Elders, MD (alumni-AR) 1990  Suzanne Dandoy, MD (alumni-VA) 1985  Joan K. Leavitt, MD (alumni-OK) 1984  Kristine Gebbie, RN (alumni-WA) website yes